JPRN-jRCT1030190143尚未招募未知
Double blind, parallel, randomized, placebo controlled research to evaluate safety and efficacy of the 5-aminolevulinic phosphate (5-ALA PO4), sodium ferrous citrate (SFC) and zinc (Zn) with asymptomatic malaria parasite carriers
Kano Shigeyuki0 个研究点目标入组 200 人开始时间: 2019年11月27日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 65age old（—）
- 性别
- All
入选标准
- •1.Participant who is able to give written informed consent
- •2.Male or female subject of 18 year to 65 year inclusive
- •3.Weighing 35 to 90 kg
- •4.Presence of malaria parasite of all species inclusive in blood confirmed by DNA amplification test
- •5.Women with child bearing potential willing to give consent for pregnancy test
排除标准
- •1.Participant with signs and symptoms of malaria
- •2.Known history of hypersensitivity, allergic or adverse reactions to 5-aminolevulinic acid, sodium ferrous citrate and Zn
- •3.Participant is pregnant or lactating women
- •4.Have taken any medication with antimalarial or antibiotic with antimalarial effect in previous 30 days
研究者
相似试验
进行中（未招募）
不适用
Double blind, comparative, randomized, placebo controlled, clinical study of therapeutic equivalence and tolerability of the topical preparation Terbinafine cream 1% (Pliva Croatia) with the medical preparation Lamisil (terbinafine 1% cream), for patients affected from uncomplicated Tinea pedis (Athlete´s Foot).ncomplicated Tinea pedis.EUCTR2006-000775-15-CZPLIVA - ISTRAŽIVANJE I RAZVOJ d.o.o.770
进行中（未招募）
1 期
Efficacy and safety evaluation of umbilical cord mesenchymal stem cells for the treatment of patients with respiratory failure due to coronavirus (COVID-19)EUCTR2020-001505-22-ESBanc de Sang i Teixits25
进行中（未招募）
不适用
Randomized, double blind, parallel groups, placebo controlled pivotal clinical trial to asses preliminary efficacy and security of a sublingual Cannabis Standardized Extract (Sativex) added to reference treatment for prevention and treatment of nausea and late vomiting induced by moderately emetogenic chemotherapy. - SATEME-08Chemotherapy induced nausea and vomitingEUCTR2004-003824-36-ESFundació Institut Català de Farmacologia
进行中（未招募）
1 期
Multicenter clinical trial to evaluate efficacy and safety of diclofenac 1% gel produced by Epifarma s.r.l. compared to Voltaren® Emulgel® 1% gelPatients with acute painful and flogistic (inflammatory) disease due to acute traumatic events (injury/contusion) of joints, muscles, tendons and ligamentsEUCTR2015-001779-29-HUEpifarma s.r.l.749
进行中（未招募）
1 期
Elsiglutide will be administered to patients with colorectal cancer along with chemotherapy, to assess the efficacy of elsiglutide in preventing the Chemotherapy Induced Diarrhea (CID). Elsiglutide will be given at different doses including placebo group.Chemotherapy Induced Diarrhea (CID)MedDRA version: 18.0Level: LLTClassification code 10056985Term: Diarrhoea post chemotherapySystem Organ Class: 100000004856EUCTR2014-000998-39-BGHelsinn Healthcare SA600